Perrigo (PRGO) Net Cash Flow Growth (1y) (2014 - 2026)
Perrigo (PRGO) Net Cash Flow Growth (1y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -117.27% |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | -167.84% |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -290.21% |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 270.63% |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -367.42% |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | -7.60% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 272.00% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Perrigo | 1.91 Bn | 1.51 Bn | 313.90 Mn | 138.12% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 27, 2026 | 138.12% |
| Mar 28, 2026 | -12.70% |
| Dec 31, 2025 | 110.98% |
| Sep 27, 2025 | -102.20% |
| Jun 28, 2025 | 115.93% |
| Mar 29, 2025 | -78.19% |
| Dec 31, 2024 | -721.80% |
| Sep 28, 2024 | 1,698.42% |
| Jun 29, 2024 | -113,500.00% |
| Mar 30, 2024 | -67.58% |
| Dec 31, 2023 | 20.36% |
| Sep 30, 2023 | 1,174.47% |
| Jul 1, 2023 | 99.99% |
| Apr 1, 2023 | -156.62% |
| Dec 31, 2022 | 157.18% |
| Oct 1, 2022 | -100.27% |
| Jul 2, 2022 | -886.43% |
| Apr 2, 2022 | 157.22% |
| Dec 31, 2021 | 6.04% |
| Oct 2, 2021 | 383.12% |